IBD 50 Shows Lots Of Stocks Poised To Break Out Investor's Business Daily Look at Alexion Pharmaceuticals (ALXN), whose drugs target cancer, autoimmune disorders and transplant rejection. The stock has shaped a tight, low-volume flat base. The buy point comes in at 70.52, although the base is a risky late-stage pattern. ... Barclays Capital (BCS) Analysts Now Covering Alexion Pharmaceuticals (ALXN) Stock |
